The relationship between apelin and parathyroid hormone in hemodialysis patients

Renal Failure

Volumn 34, Issue 8, 2012, Pages 970-973

  Mafra, Denise ^a   Lobo, Julie C ^b   Farage, Najla E ^c   Stockler Pinto, Milena B ^b   Leal, Viviane O ^a   Calixto, Antonio ^d   Geloneze, Bruno ^d  

^a FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c Renalcor Clinic   (Brazil)

^d UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Apelin; Bone mineral density; Chronic kidney disease; Hemodialysis; Parathyroid hormone

Indexed keywords

APELIN; PARATHYROID HORMONE;

ADULT; ARTICLE; BONE DENSITY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEMODIALYSIS; HUMAN; MALE; PARATHYROID HORMONE BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

BONE DENSITY; CASE-CONTROL STUDIES; FEMALE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; PARATHYROID HORMONE; REFERENCE VALUES; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84865271654     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/0886022X.2012.700675     Document Type: Article

References (15)

1. Tatemoto K, Hosoya M, Habata Y, et al. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun. 1998;251:471-476.
2. Boucher J, Masri B, Daviaud D, et al. Apelin, a newly identified adipokine up-regulated by insulin and obesity. Endocrinology. 2005;146:1764-1771.
3. Lago F, Dieguez C, Gómez-Reino J, Gualillo O. The emerging role of adipokines as mediators of inflammation and immune responses. Cytokine Growth Factor Rev. 2007;18:313-325.
4. XieH,TangSY, CuiRR, et al.Apelin and its receptor are expressed in human osteoblasts. Regul Pept. 2006;134: 118-125.
5. Tang SY, Xie H, Yuan LQ, et al. Apelin stimulates proliferation and suppresses apoptosis of mouse osteoblastic cell line MC3T3-E1 via JNK and PI3-K/Akt signaling pathways. Peptides. 2007;28:708-718.
6. Komaba H, Goto S, Fukagawa M. Critical issues of PTH assays in CKD. Bone. 2009;44:666-670.
7. Frisancho AR. New norms of upper limb fat and muscle areas for assessment of nutritional status. Am J Clin Nutr. 1981; 34:2540-2545.
8. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42(Suppl. 3):S1-S201.
9. Malyszko J, Malyszko JS, Kozminski P, Mysliwiec M. Apelin and cardiac function in hemodialyzed patients: Possible relations?Am J Nephrol. 2006;26:121-126.
10. Foldes G, Horkay F, Szokodi I, et al. Circulating and cardiac levels of apelin, the novel ligand of the orphan receptor APJ, in patients with heart failure. Biochem Biophys Res Commun. 2003;308:480-485.
11. Malyszko J, Malyszko JS, Pawlak K, Mysliwiec M. Visfatin and apelin, new adipocytokines, and their relation to endothelial function in patients with chronic renal failure. Adv Med Sci. 2008;53:32-36.
12. Codognotto M, Piccoli A, Zaninotto M. Evidence for decreased circulating apelin beyond heart involvement in uremic cardiomyopathy. Am J Nephrol. 2007;27:1-6.
13. Zhang DL, Liao H, Wei YY. Elevation of serum apelin-13 is positively correlated with ADMA in patients on maintenance hemodialysis. Clin Nephrol. 2009;71:405-412.
14. Xie H, Yuan LQ, Luo XH. Apelin suppresses apoptosis of human osteoblasts. Apoptosis. 2007;12:247-254.
15. Ott SM. Review article: Bone density in patients with chronic kidney disease stages 4-5. Nephrology. 2009;14:395-403.